Publications by authors named "Peter Sharplin"

Claim this Profile
P
Primary prevention of pediatric abusive head trauma: a cost audit and cost-utility analysis.
Joshua Friedman, Peter Reed, Peter Sharplin, Patrick Kelly

Child Abuse Negl· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
Peter Sharplin, Jason Gordon, John R Peters, Anthony P Tetlow, Andrea J Longman

Cardiovasc Diabetol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.
Peter Sharplin, Jason Gordon, John R Peters, Anthony P Tetlow, Andrea J Longman

Cardiovasc Diabetol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Peter Mullins, Peter Sharplin, Hannele Yki-Jarvinen, Matthew C Riddle, Hans-Ulrich Haring

Clin Ther· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.
Craig J Currie, Christopher Ll Morgan, Chris D Poole, Peter Sharplin, Morten Lammert

Curr Med Res Opin· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications.
Craig J Currie, Christopher Ll Morgan, Simon Dixon, Phil McEwan, Nick Marchant, Peter Sharplin

Diabetes Res Clin Pract· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
Jeremy Holmes, David Dunlop, Lindsay Hemmett, Peter Sharplin, Uday Bose

Pharmacoeconomics· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death.
Craig J Currie, Christopher Ll Morgan, Simon Dixon, Phil McEwan, Nick Marchant, Peter Sharplin

Diabetes Res Clin Pract· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis